Now showing items 1-10 of 19
Treating the ineligible: Disease modification in people with multiple sclerosis beyond NHS England commissioning policies.
(Elsevier/Science Direct, 2018-11-02)
BACKGROUND: Whilst there is a broad selection of drugs licensed as disease modifying treatments (DMTs) for people with relapsing multiple sclerosis (pwRMS), access to DMTs remains restricted, particularly for people with ...
Cladribine Personalised Dosing to Treat Active Multiple Sclerosis - Follow-up in 250 patients
This is the accepted manuscript of an article published online: 1. ACTRIMS Forum 2021 – Poster Presentations. Multiple Sclerosis Journal. 2021;27(1_suppl):15-122. doi:10.1177/13524585211015908
Cladribine to halt deterioration in people with advanced multiple sclerosis (CHARIOTMS)
Meeting abstract P0196 from MSVirtual 2020 – 8th Joint ACTRIMS-ECTRIMS Meeting, September 11-13, 2020